Results 31 to 40 of about 3,343,278 (165)

In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels

Neurobiology of Disease, 2012
Evidence for an involvement of striatal D1 receptors in levodopa-induced dyskinesia has been presented whereas the contribution of striatal D2 receptors remains controversial.
Flora Mela, Matteo Marti, Simone Bido, M. Angela Cenci, Michele Morari   +4 more
doaj   +1 more source

Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study

Neural Regeneration Research, 2021
Growing evidence has highlighted that angiotensin-converting enzyme (ACE)-inhibitors (ACEi)/AT1 receptor blockers (ARBs) may influence the complex interplay between dopamine and the renin-angiotensin system in the nigrostriatal pathway, thus affecting ...
Elena Contaldi, Luca Magistrelli, Anna V Milner, Marco Cosentino, Franca Marino, Cristoforo Comi   +5 more
doaj   +1 more source

Cognitive Outcome After Deep Brain Stimulation for Refractory Obsessive–Compulsive Disorder: A Systematic Review

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Introduction Deep brain stimulation (DBS) is an effective treatment for refractory obsessive–compulsive disorder (OCD). Neuropsychological assessment contributes to DBS treatment in several ways: it monitors the cognitive safety of the treatment, identifies beneficial or detrimental cognitive side effects and it could aid to explain ...
Tim A. M. Bouwens van der Vlis, Annelien Duits, Mégan M. G. H. van de Veerdonk, Anne E. P. Mulders, Koen R. J. Schruers, Yasin Temel, Linda Ackermans, Albert F. G. Leentjens   +7 more
wiley   +1 more source

Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease

eNeurologicalSci, 2020
Background: Dopamine replacement therapy is an established treatment for motor symptoms of Parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia.
Shoko Kakinuma, Minako Beppu, Setsu Sawai, Akitoshi Nakayama, Shigeki Hirano, Yoshitaka Yamanaka, Tatsuya Yamamoto, Chigusa Masafumi, Xiamuxiya Aisihaer, Alimasi Aersilan, Yue Gao, Kenichi Sato, Itoga Sakae, Takayuki Ishige, Motoi Nishimura, Kazuyuki Matsushita, Mamoru Satoh, Fumio Nomura, Satoshi Kuwabara, Tomoaki Tanaka   +19 more
doaj   +1 more source

Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease [PDF]

, 2014
Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia. We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
Mohamed Ibrahim, Norlinah, Tan, Huijan, Raymond, Azman Ali, Wan Yahya, Nafisah, Hashim, Hasnur Zaman, Tamil, Azmi Mohd   +5 more
core   +1 more source

Neuroanatomical and Microglial Alterations in the Striatum of Levodopa-Treated, Dyskinetic Hemi-Parkinsonian Rats

Frontiers in Neuroscience, 2020
Dyskinesia associated with chronic levodopa treatment in Parkinson’s disease is associated with maladaptive striatal plasticity. The objective of this study was to examine whether macroscale structural changes, as captured by magnetic resonance imaging ...
Edward J. R. Fletcher, Clare J. Finlay, Ana Amor Lopez, William R. Crum, Anthony C. Vernon, Anthony C. Vernon, Susan Duty   +6 more
doaj   +1 more source

Different Alterations of Agonist and Antagonist Binding to 5-HT Receptor in a Rat Model of Parkinson’s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study

Journal of Parkinson’s Disease, 2021
Background: The gold-standard treatment for Parkinson’s disease is L-DOPA, which in the long term often leads to levodopa-induced dyskinesia. Serotonergic neurons are partially responsible for this, by converting L-DOPA into dopamine leading to its ...
Benjamin Vidal, Elise Levigoureux, Sarah Chaib, Caroline Bouillot, Thierry Billard, Adrian Newman-Tancredi, Luc Zimmer   +6 more
doaj   +1 more source

Retrospective Multicenter Study on Outcome Measurement for Dyskinesia Improvement in Parkinson’s Disease Patients with Pallidal and Subthalamic Nucleus Deep Brain Stimulation

Brain Sciences, 2022
Deep brain stimulation (DBS) is an effective treatment for dyskinesia in patients with Parkinson’s disease (PD), among which the therapeutic targets commonly used include the subthalamic nucleus (STN) and the globus pallidus internus (GPi).
Fangang Meng, Shanshan Cen, Zhiqiang Yi, Weiguo Li, Guoen Cai, Feng Wang, Stephan S. Quintin, Grace E. Hey, Jairo S. Hernandez, Chunlei Han, Shiying Fan, Yuan Gao, Zimu Song, Junfei Yi, Kailiang Wang, Liangwen Zhang, Adolfo Ramirez-Zamora, Jianguo Zhang   +17 more
doaj   +1 more source

White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease

, 2022
Background: Although levodopa-induced dyskinesia-relevant white matter change has been evaluated, it is uncertain whether these changes may reflect the underlying predisposing conditions leading to the development of levodopa-induced dyskinesia ...
이영건, 이양현, 이필휴, 손영호, 정석종, 유한수, 예병석, 백경원, 이혜선   +8 more
core   +1 more source

Cortico-striatal gamma oscillations are modulated by dopamine D3 receptors in dyskinetic rats

Neural Regeneration Research
Long-term levodopa administration can lead to the development of levodopa-induced dyskinesia. Gamma oscillations are a widely recognized hallmark of abnormal neural electrical activity in levodopa-induced dyskinesia.
Pengfei Wang, Yuewei Bi, Min Li, Jiazhi Chen, Zhuyong Wang, Huantao Wen, Ming Zhou, Minjie Luo, Wangming Zhang   +8 more
doaj   +1 more source